Abstract: SA-PO0190
Patients with Amyloidosis on Kidney Replacement Therapy: A Propensity-Score Matched Survival Analysis
Session Information
- Onconephrology: MGRS, HSCT, Electrolytes, RCC, and More
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Onconephrology
- 1700 Onconephrology
Authors
- Jayanti, Sumedh, Westmead Hospital, Westmead, New South Wales, Australia
- Sabanayagam, Dharshana, The University of Sydney School of Public Health, Sydney, New South Wales, Australia
- Bose, Bhadran, Nepean Hospital, Penrith, New South Wales, Australia
- Chau, Katrina, Blacktown & Mount Druitt Hospital, Blacktown, New South Wales, Australia
- Kwok, Fiona, Westmead Hospital, Westmead, New South Wales, Australia
- Li, Jennifer, Westmead Hospital, Westmead, New South Wales, Australia
Background
Renal amyloidosis is rare and challenging to manage in those with kidney failure. We hypothesise that these patients have worse prognosis on kidney replacement therapy (KRT) compared with other causes of kidney failure.
Methods
A propensity-matched survival analysis was conducted using retrospective data from the Australia and New Zealand Dialysis and Transplant Registry, including patients who commenced KRT between 1990–2022. Dialysis and transplant patients were matched for age, sex, treatment era, comorbidities and dialysis vintage at a 1:4 ratio for amyloidosis to comparator groups including polycystic kidney disease (PCKD), glomerulonephritis and diabetes.
Results
There were 84,148 prevalent dialysis patients, with 654 (0.77%) having amyloidosis. Compared with matched cohorts, dialysis patient survival was worse in amyloidosis than diabetic nephropathy (HR 0.68, 95%CI 0.62–0.74), glomerulonephritis (HR 0.38, 95%CI 0.34–0.42) and PCKD (HR 0.28, 95%CI 0.26–0.32)(Figure1). There were 23,463 prevalent transplant recipients, with 48 (0.20%) having amyloidosis. Post-transplant survival for amyloidosis patients was comparable to kidney failure due to type 2 diabetes (HR 1.00, 95%CI 0.75–1.35), but worse than type 1 diabetes (HR 0.72, 95%CI 0.52–0.98), glomerulonephritis (HR 0.40, 95%CI 0.28–0.57) and PCKD (HR 0.40, 95%CI 0.28–0.56) (Figure 2).
Conclusion
Amyloidosis patients had similar post-transplant survival to those with kidney failure from type 2 diabetes, but worse survival regardless of KRT modality compared with other kidney diseases. Further research should explore amyloidosis subtype-specific prognoses to guide personalised care.
Propensity-Score Matched Survival Analysis of Dialysis Patients from 1990-2022.
Propensity-Score Matched Survival Analysis of Transplant Recipients from 1990-2022